634 a:4:{s:8:"template";a:5:{s:48:"/var/www/resverlogix/app/views/page/landing.html";b:1;s:20:"page/navigation.html";b:1;s:14:"page/head.html";b:1;s:14:"page/hero.html";b:1;s:14:"page/tail.html";b:1;}s:9:"timestamp";i:1546455527;s:7:"expires";i:1546459127;s:13:"cache_serials";a:3:{s:72:"/var/www/resverlogix/var/templates_c/%%5C^5C9^5C9C394F%%landing.html.inc";s:32:"71b04b1c96bed0ed1b5e511d1c39003c";s:69:"/var/www/resverlogix/var/templates_c/%%AD^AD7^AD761F1B%%head.html.inc";s:32:"0bce22ff82987b7d4da594a05988f1a6";s:69:"/var/www/resverlogix/var/templates_c/%%BC^BC7^BC746C8E%%tail.html.inc";s:32:"39313bf8c1e668f5a8912644f3251a3a";}}{nocache:71b04b1c96bed0ed1b5e511d1c39003c#0}

Science

Resverlogix is bringing safe, affordable, first-in-class epigenetic therapeutics to people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Our lead drug candidate, apabetalone, is currently in a fully enrolled Phase 3 clinical trial, BETonMACE.

Explore

Investors

Resverlogix (TSX:RVX) is a late-stage biotech company with a novel epigenetic approach to reducing the incidence of Major Adverse Cardiac Events (MACE) in high-risk patients. Explore Resverlogix’s advanced clinical platform and discover why now is the time to engage.

Engage

NEWS

Home($params);?>

APABETALONE: a relative size animation

{nocache:71b04b1c96bed0ed1b5e511d1c39003c#1}